EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
Frequently asked questions
What sector does EyeGene Inc (185490) operate in?
EyeGene Inc belongs to the Energy sector and operates in the Biotechnology industry.
What is EyeGene Inc (185490) current stock price?
As of the latest data, EyeGene Inc stock price is ₩1,725, with a previous close of ₩1,680. EyeGene Inc gained ₩45 in the last trading session, representing a 2.68% increase.
What is EyeGene Inc (185490) current market capitalization?
EyeGene Inc market cap is approximately 74.56 billion.
What is EyeGene Inc (185490) EBITDA?
EyeGene Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.62 billion.
Does EyeGene Inc (185490) pay dividends?
No. EyeGene Inc does not pay a dividend.
What is EyeGene Inc (185490) beta (volatility) score?
EyeGene Inc has a beta of 0.705, indicating lower volatility than the overall market.
